Skip to content

Effect of Chuna Manipulation Therapy on Gait in Patients With Lumbar Disc Herniation

Prospective Observation Study of the Effect of Chuna Manipulation Therapy on Gait in Patients With Lumbar Disc Herniation

Status
Withdrawn
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03858556
Enrollment
0
Registered
2019-02-28
Start date
2019-02-27
Completion date
2019-02-27
Last updated
2019-03-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lumbar Disc Herniation, Gait Analysis, Manual Therapy

Keywords

gait, effectiveness, treatment, Lumbar intervertebral disc herniation, Chuna

Brief summary

Prospective Observation Study of the Effect of Chuna Manipulation Therapy on Gait in Patients With Lumbar Disc Herniation

Detailed description

To investigate the effect of Chuna manual therapy on gate, 20 patients with lumbar disc herniation were studied. The gait analysis was performed before the first treatment, after the seventh treatment, after the 14th treatment, and compared with the data of 20 normal subjects.

Interventions

Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation will be administered to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.

Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).

Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).

Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).

PROCEDUREAcupuncture

Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.

PROCEDUREElectroacupuncture

Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.

PROCEDURECupping

Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.

Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.

Sponsors

Jaseng Medical Foundation
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
19 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Lumbar intervertebral disc herniation as confirmed by a doctor of medicine or a doctor of Korean medicine through an MRI * Patients with radiculopathy * Patients aged 19 to 60 * Patients with an Oswestry Disability Index (ODI) of ≥10 * Patients who have agreed to participate in the clinical study and given written informed consent

Exclusion criteria

* Patients who were unable to walk for more than 5 minutes due to pain * Patients with a serious disease that may limit gait(such as spinal metastasis of the tumor, acute fracture and spinal dislocation) * Patients with chronic conditions that may interfere with the interpretation of the therapeutic effect or outcome(such as chronic kidney failure) * Patients with progressive neurological deficit or severe neurological symptoms such as spinal cord injury * Patients with severe mental illness * Patients who are currently on on steroids, immunosuppressants, psychiatric medications, or other medications that can affect outcome * Patients who are pregnant or planning a pregnancy * Patients who are participating in other clinical studies or if it is difficult for you to participate in clinical research as determined by the researcher

Design outcomes

Primary

MeasureTime frameDescription
Gait parameter changebaseline, 2 weeks after baseline\- Time parameters(step time)

Secondary

MeasureTime frameDescription
SLRbaseline, 2 weeks after baselineStraight Leg Raise test(SLR)
ODIbaseline, 2 weeks after baselineOswestry Disability Index(ODI)
EQ-5Dbaseline, 2 weeks after baselineEuroQol-5 Dimension(EQ-5D)
Lumbar ROMbaseline, 2 weeks after baselineLumbar Range of Motion(ROM) (Flexion/Extension/Lateral flexion/Rotation)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026